Arbutus Biopharma Corporation
ABUS
$3.23
-$0.28-7.98%
| Weiss Ratings | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.69 | |||
| Price History | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.22% | |||
| 30-Day Total Return | -3.29% | |||
| 60-Day Total Return | -3.58% | |||
| 90-Day Total Return | -7.98% | |||
| Year to Date Total Return | -1.82% | |||
| 1-Year Total Return | 3.53% | |||
| 2-Year Total Return | 11.38% | |||
| 3-Year Total Return | 5.21% | |||
| 5-Year Total Return | 210.58% | |||
| 52-Week High % Change | -31.64% | |||
| 52-Week Low % Change | 22.81% | |||
| Price | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.73 | |||
| 52-Week Low Price | $2.63 | |||
| 52-Week Low Price (Date) | May 02, 2024 | |||
| 52-Week High Price (Date) | Sep 09, 2024 | |||
| Valuation | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 618.48M | |||
| Enterprise Value | 501.98M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.38 | |||
| Earnings Per Share Growth | -13.40% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 99.38 | |||
| Price/Book (Q) | 6.30 | |||
| Enterprise Value/Revenue (TTM) | 81.34 | |||
| Price | $3.23 | |||
| Enterprise Value/EBITDA (TTM) | -6.94 | |||
| Enterprise Value/EBIT | -6.81 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 189.70M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 267 469 0914 | |||
| Address | 701 Veterans Circle Warminster, PA 18974 | |||
| Website | www.arbutusbio.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,194.19% | |||
| Profit Margin | -1,133.04% | |||
| Management Effectiveness | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -33.36% | |||
| Return on Equity | -- | |||
| Income Statement | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 6.17M | |||
| Total Revenue (TTM) | 6.17M | |||
| Revenue Per Share | $0.03 | |||
| Gross Profit (TTM) | -47.87M | |||
| EBITDA (TTM) | -72.31M | |||
| EBIT (TTM) | -73.69M | |||
| Net Income (TTM) | -69.92M | |||
| Net Income Avl. to Common (TTM) | -69.92M | |||
| Total Revenue Growth (Q YOY) | -26.62% | |||
| Earnings Growth (Q YOY) | 35.11% | |||
| EPS Diluted (TTM) | -0.38 | |||
| EPS Diluted Growth (Q YOY) | 40.05% | |||
| Balance Sheet | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 122.62M | |||
| Cash Per Share (Q) | $0.65 | |||
| Total Current Assets (Q) | 127.32M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 97.37M | |||
| Current Ratio (Q) | 8.152 | |||
| Book Value Per Share (Q) | $0.51 | |||
| Total Assets (Q) | 131.71M | |||
| Total Current Liabilities (Q) | 15.62M | |||
| Total Debt (Q) | 6.12M | |||
| Total Liabilities (Q) | 34.34M | |||
| Total Common Equity (Q) | 97.37M | |||
| Cash Flow | ABUS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 22.95M | |||
| Cash from Financing (TTM) | 52.00M | |||
| Net Change in Cash (TTM) | 10.05M | |||
| Levered Free Cash Flow (TTM) | -41.56M | |||
| Cash from Operations (TTM) | -64.85M | |||
